These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38416196)

  • 1. Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations.
    Mohite P; Lokwani DK; Sakle NS
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Aug; 397(8):6107-6119. PubMed ID: 38416196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
    Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
    Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K
    So EC; Liu PY; Wu SN
    Eur J Pharmacol; 2020 Jul; 879():173141. PubMed ID: 32353360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Sodium-Glucose Co-Transporter 2 Inhibitors Combined with Metformin on Pancreatic Cancer Cell Lines.
    Cristovão A; Andrade N; Martel F; Silva C
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
    Zügner E; Yang HC; Kotzbeck P; Boulgaropoulos B; Sourij H; Hagvall S; Elmore CS; Esterline R; Moosmang S; Oscarsson J; Pieber TR; Peng XR; Magnes C
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
    Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
    Nakano D; Kawaguchi T; Iwamoto H; Hayakawa M; Koga H; Torimura T
    PLoS One; 2020; 15(4):e0232283. PubMed ID: 32343721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
    Bardaweel S; Issa A
    J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin: A sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling.
    Zhan G; Wang X; Wang X; Li J; Tang Y; Bi H; Yang X; Xia Y
    Eur J Pharmacol; 2024 Sep; 978():176712. PubMed ID: 38906237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dapagliflozin on diabetic patients with cardiovascular disease via MAPK signalling pathway.
    Yue Z; Li L; Fu H; Yin Y; Du B; Wang F; Ding Y; Liu Y; Zhao R; Zhang Z; Yu S
    J Cell Mol Med; 2021 Aug; 25(15):7500-7512. PubMed ID: 34258872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
    Li X; Römer G; Kerindongo RP; Hermanides J; Albrecht M; Hollmann MW; Zuurbier CJ; Preckel B; Weber NC
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study.
    Kuoni S; Steiner R; Saleh L; Lehmann R; Ochsenbein-Kölble N; Simões-Wüst AP
    Biomed Pharmacother; 2024 Feb; 171():116177. PubMed ID: 38262151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative
    Karim S; Alghanmi AN; Jamal M; Alkreathy H; Jamal A; Alkhatabi HA; Bazuhair M; Ahmad A
    Oncol Res; 2024; 32(5):817-830. PubMed ID: 38686050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
    Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y
    Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells.
    Lin Y; Nan J; Shen J; Lv X; Chen X; Lu X; Zhang C; Xiang P; Wang Z; Li Z
    EBioMedicine; 2020 Feb; 52():102637. PubMed ID: 31981975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination.
    Ren K; Wang X; Ma R; Chen H; Min T; Ma Y; Xie X; Wang W; Deng X; Zhou Z; Li K; Zhu K; Hao N; Dang C; Sun T; Zhang H
    Eur J Pharmacol; 2024 Nov; 983():177002. PubMed ID: 39293571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
    Cai J; Divino V; Burudpakdee C
    Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
    Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
    Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.